Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic. Found 12 abstracts

Schmier J, Ogden K, Nickman N, Halpern MT, Cifaldi M, Ganguli A, Bao Y, Garg V. Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. Clinical therapeutics. 2017 Aug;39(8):1600-17.
Hochster HS, Uboha N, Messersmith W, Gold PJ, O Neil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23.
Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, Zhang L, Abbattista A, Davis C, Gallo Stampino C, Borghaei H. A first-in-human study of the anti-alpha5beta1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Nov;74(5):1039-46.   PMCID: Pmc4209234
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10;24(26):4324-32.
Lauritsen JP, Haks MC, Lefebvre JM, Kappes DJ, Wiest DL, Chen X, Arciero CA, Godwin AK, Barsevick AM, Whitmer K, Nail LM, Beck SL, Dudley WN, Weiner LM, Treat J. Role of the transcription factor Th-POK in CD4:CD8 lineage commitment. . Immunological reviews. 2006 Feb;209(2):237-52.
Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D, Johnson DH. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. Journal of the National Cancer Institute. 2002 Feb 06;94(3):173-81.
Langer CJ. The emerging world role of irinotecan in lung cancer. Oncology (Huntingt). 2001 Jul;15(7 Suppl 8):15-21.
Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Jun;77(3):446-9.
Ozols RF. The role of gemcitabine in the treatment of ovarian cancer. Semin Oncol. 2000 Feb;27(1 Suppl 2):40-7.
Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000 Jul;18(14):2780-7.
Ross EA, Moore D. Modeling clustered, discrete, or grouped time survival data with covariates. Biometrics. 1999 Sep;55(3):813-9.
Lee WR, Hanlon AL, Hanks GE. Systematic biopsies: Do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone?. Radiology. 1996 Feb;198(2):439-42.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic

therapeutic drug therapy use Female therapeutic use administration & dosage Human adverse effects Aged Antineoplastic Combined Chemotherapy Protocols US Gov't Support-PHS Male Survival Analysis Adult analogs & derivatives Middle Aged metabolism Lung Neoplasms Intravenous Infusions Antineoplastic Agents pathology Treatment Outcome Ovarian Neoplasms Disease-Free Survival Deoxycytidine Drug Administration Schedule Paclitaxel genetics adverse Neoplasms Monoclonal Antibodies effects Antineoplastic Antimetabolites pharmacokinetics United States immunology Non-US Gov't Support Drug Dose-Response Relationship Middle Age Monoclonal Antibodies-Humanized Camptothecin 80 and over Aged Cisplatin Clinical Trials Non-Small-Cell Lung Carcinoma Creatinine Likelihood Functions Enzyme-Linked Immunosorbent Assay antibodies Nausea Mice erbB-2 Genes radiology Cervix Neoplasms arthritis Drug Synergism complications Rheumatoid Arthritis Economic Models rheumatoid methods Neoplastic Gene Expression Regulation Statistical Data Interpretation neoplasms antagonists & inhibitors Randomized Controlled Trials Japan Statistical Models blood 103882-84-4 (gemcitabine) therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols statistics & numerical data NIH Research Support-Extramural Kidney Failure analogs & Flushing surgery MAP Kinase Kinase Kinases Retrospective Studies 15663-27-1 (Cisplatin) Infliximab Random Allocation Neoplasm Staging Biometry Antirheumatic Agents Cohort Studies Liver Function Tests Hospital Costs Colorectal Neoplasms Prognosis Neoplasm Drug Resistance Bilirubin Phytogenic Antineoplastic Agents Predictive Value of Tests Etoposide Genetic Engineering Diabetic Retinopathy derivatives Biological Tumor Markers Aspartate Aminotransferases Non-Small-Cell Lung therapeutic use MH - Carcinoma Rituximab Protein Kinase Inhibitors Area Under Curve hospital costs 0 (bevacizumab) Monoclonal) 0 (Antibodies monoclonal Proto-Oncogene Proteins radiotherapy Blindness erbB-2 Receptor diagnosis therapeutic use MH - Clinical Tr Light Coagulation 0 (Antineoplastic Combined Chemotherapy Protocols) Topotecan Mutation Non-US Gov't Research Support prostate economics chemically induced Quality of Life physiology Breast Neoplasms Squamous Cell Carcinoma Linear Models Fatigue Liver Diseases Neoplasm Proteins humanized Dimerization Benzimidazoles Topoisomerase I Inhibitors Hypotension Aging Integrin alpha5beta1 Drug Tolerance Home Infusion Therapy Adjuvant Radiotherapy volume infliximab drug therapy MH - Cisplatin isolation & purification prevention & control Early Termination of Clinical Trials 951-77-9 (Deoxycytidine) Metabolic Clearance Rate Pilot Projects biopsy
Last updated on Friday, August 14, 2020